Biogen Idec receives approval in the European Union for AVONEX(R) PEN(TM)
7 June 2011 | By Biogen Idec
Biogen Idec announced that the European Commission has granted approval to AVONEX PEN...
List view / Grid view
News
New data in breast and ovarian cancer presented at ASCO support continued development of Iniparib
6 June 2011 | By Sanofi
Sanofi announced new data for iniparib (BSI-201)...
Children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease
6 June 2011 | By GlaxoSmithKline
GSK has made a new offer to supply its rotavirus vaccine, to the GAVI Alliance...
Merck and ARIAD announce presentation of results of Phase III SUCCEED trial
6 June 2011 | By Merck
Merck and ARIAD Pharmaceuticals, Inc., announced the presentation of detailed results from the Phase III SUCCEED clinical trial...
ALMSCO International highlights its BenchTOF-dx for improved sensitivity
6 June 2011 | By The Scott Partnership
ALMSCO International, showcasing its state-of-the-art bench-top TOF mass spectrometer, BenchTOF-dx at ASMS 2011...
Thermo Fisher Scientific introduces new capabilities for comprehensive qualitative and quantitative proteomics
Thermo Fisher Scientific Inc., the world leader in serving science, today introduced new capabilities for laboratories performing a wide range of qualitative and quantitative proteomics workflows.
Novartis gains European Commission approval for Lucentis®
6 June 2011 | By Novartis
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab)...
ZALTRAP™ (aflibercept) significantly improved survival in previously treated metastatic colorectal cancer patients
6 June 2011 | By Sanofi
Data will be presented at the ESMO World Congress on Gastrointestinal Cancer...
Merck commends GAVI Alliance on continued efforts to improve access
5 June 2011 | By Merck
Merck commends the GAVI Alliance for their commitment to protecting the lives of children...
Patients with deadly form of lung cancer lived longer without disease worsening
5 June 2011 | By Eli Lilly and Company
Eli Lilly and Company announced that PARAMOUNT, met its primary endpoint of progression-free survival...
Second Phase 3 Study of YERVOY™ (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
5 June 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a second Phase 3 randomized, double blind study...
Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations
5 June 2011 | By Roche
Roche announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival in people with previously untreated BRAF V600 mutation...
Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer
4 June 2011 | By Roche
Roche announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin)...
Late-breaking ASCO data demonstrate circulating tumor cells as potential biomarker for metastatic prostate cancer clinical trials
4 June 2011 | By Johnson & Johnson
This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival...
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas
4 June 2011 | By GlaxoSmithKline
Results of the PALETTE study presented at the 2011 Annual Meeting of the ASCO...
